Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPeking Union Medical College Hospital
About this trial
The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-LM3 PET/CT and compare it with 68Ga-DOTATATE PET/CT in patients with pheochromocytoma/paraganglioma (PPGL).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 to 80 years.
Suspected or confirmed PPGL patients.
Disqualifiers
Combined with other types of tumors.
Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR<30ml/min).
Pregnant or breast-feeding women.
Inability to perform PET/CT scans.
Trial design
Design model
Single group
Treatments tested in this trial
Diagnostic Test: Al18F-NOTA-LM3
DrugPatients will receive a single intravenous injection of Al18F-NOTA-LM3. Subsequently, a PET/CT scan will be performed within 60 to 120 minutes post-injection.
Diagnostic Test: 68Ga-DOTATATE
DrugPatients will receive a single intravenous injection of 68Ga-DOTATATE. Subsequently, a PET/CT scan will be performed within 40 to 60 minutes post-injection.
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: Al18F-NOTA-LM3 and 68Ga-DOTATATE PET/CT scanExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Tumor Detection Rate
Compare the number of tumor detected by Al18F-NOTA-LM3 PET/CT and 68Ga-DOTATATE PET/CT
Time frame
From study completion to 6 months after completion.Secondary outcomes
1
Standardized Uptake Value (SUV) of Tumor
Compare the SUVmax of tumor derived from Al18F-NOTA-LM3 and 68Ga-DOTATATE PET/CT.
Time frame
From study completion to 6 months after completion.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov